Abstract
This article examines the ethical issues raised by the pricing of priceless goods. Priceless goods are defined as ones that are widely held to have some special non-market value that makes them unsuited for buying and selling. One subset of priceless goods is prescription drugs-particularly life-saving and life-enhancing ones. Drug makers are under pressure to price their medicines responsibly, which means to restrain their prices (and profits). However, this article argues that it is precisely because life-saving and life-enhancing medicines are priceless that it is especially urgent to leave companies free to charge market prices for them.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 451-480 |
| Number of pages | 30 |
| Journal | Business Ethics Quarterly |
| Volume | 12 |
| Issue number | 4 |
| DOIs | |
| State | Published - Oct 2002 |
| Externally published | Yes |